OBJECTIVE: To assess immune-based gene therapy in a murine floor of mouth (FOM) squamous cell carcinoma (SCC) model.
STUDY DESIGN: In vitro and in vivo testing of immune therapy for SCC.
METHODS: Multiple SCC lines were infected by using advRSV-interleukin-12 (IL-12) and advCMV-interleukin-12/granulocyte macrophage colony-stimulating factor (IL-12/GM-CSF) and monitored for production of IL-12 and GM-CSF. Intratumoral injections of viral vectors were administered with systemic Ig-4-1BB ligand in an orthotopic murine FOM SCC model and followed for tumor size and survival.
RESULTS: In vitro, all cell lines produced substantial levels of IL-12 and GM-CSF. In vivo, tumors treated with advCMV-IL-12/GM-CSF and Ig-4-1BBL showed a striking reduction in tumor volume (vs control P < 0.0001) and improved median survival (38 days vs 19 days for control, P < 0.0001).
CONCLUSION: Combination immune-based therapies effectively improve survival in mice bearing FOM SCC over single-modality therapy.
Get full access to this article
View all access options for this article.
References
1.
JacobsCLymanGVelez-GarciaE, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol1992;10:257–63.
2.
WhitesideTLImmunobiology of head and neck cancer. Cancer Metastasis Rev2005;24:95–105.
3.
WhitesideTLTumor-induced death of immune cells: its mechanisms and consequences. Semin Cancer Biol2002;12:43–50.
4.
CalifanoJVan Der ReitPWestraW, et al. A genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res1996;56:2488–92.
5.
O'MalleyBWJr.SewellDALiD, et al. The role of interleukin-2 in combination adenovirus gene therapy for head and neck cancer. Mol Endocrinol1997;11:667–73.
6.
O'MalleyBWJr.LiDBucknerA, et al. Limitation of adenovirus-mediated interleukin-2 gene therapy for oral cancer. Laryngoscope1999;109:389–95.
7.
O'MalleyBWJr.CopeKAChenS, et al. Combination gene therapy for oral cancer in a murine model. Cancer Res1996;56:1737–41.
8.
Pham-NguyenKYangWSaxenaR, et al. Role of NK and T cells in IL-12-induced anti-tumor response against hepatic colon carcinoma. Int J Cancer1999;81:813–9.
9.
XuDGuPLiQ, et al. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation. Int J Cancer2004;109:499–506.
10.
XuDSauterBVMeseckM, et al. The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma. Gene Ther2005;12:1526–33.
11.
PanPGuPLiQ, et al. Regulation of dendritic cell function by NK cells: mechanisms underlying the synergism in the combination therapy of IL-12 and 4-1BB activation. J Immunol2004;172:4779–89.
12.
ChenLHuangTGMeseckML, et al. Rejection of metastic 4T1 breast cancer by attenuating Treg cells in combination with immune stimulation. (in press).
13.
MorettaABottinoCVitaleD, et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol2001;19:197–223.
14.
LaneirL.On guard-activating NK cell receptors. Nat Immunol2001;2:23–7.
15.
WindhagenAAndersonDECarrizosaA, et al. IL-12 induces human T cells secreting IL-10 with IFN-μ. J Immunol1996;157:1127–31.
16.
SousaCRHienySScharton-KersenT, et al. In vivo microbial stimulation induces rapid CD40 ligand-independent production of interleukin 12 by dendritic cells and their redistribution to T cell areas. J Exp Med1997;186:1799–1802.
17.
ShinEJWannaGBChoiB, et al. Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma. Laryngoscope2007;117:210–4.
18.
O'MalleyBWJr.ChenSSchwartzMR, et al. Adenovirus-mediated gene therapy for human head and neck squamous cell cancer in a nude mouse model. Cancer Res1995;55:1080–5.
19.
HanadaKTsunodaRHamadaH.GM-CSF-induced in vivo expansion of splenic dendritic cells and their strong costimulation activity. J Leukoc Biol1996: 18190.
20.
PanPYZangYWeberK, et al. OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases. Mol Ther2002;6:528–36.
